Market Overview

Antares Pharma Announces Availability of OTREXUP Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis in Children

Share:

Antares Pharma (NASDAQ: ATRS) today announced the availability of
OTREXUP™, the first U.S. Food and Drug Administration (FDA)
approved subcutaneous (SC) methotrexate (MTX) product for once weekly
self-administration with an easy-to-use, single dose, disposable auto
injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is
available at distribution centers throughout the USA.

See full press release

Posted-In: News Guidance Financing Management Global

 

Related Articles (ATRS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→